In our recent webinar, we heard from speakers at the Fred Hutchinson Cancer Research Center, who discuss how they successfully implemented and utilize the Vectra® Polaris™ and Vectra® 3 automated, multiplexed tissue imaging platforms in their core lab.
Our first speaker was Dr. Savanh Chanthaphavong, the Director of the Experimental Histopathology Core Lab at the Fred Hutchinson Cancer Research Center. The Experimental Histopathology Core Lab provides comprehensive histology and immunohistochemistry services, including cell and tissue harvesting, cell pellet-making, TMA construction, tissue processing, and H&E/special staining. They also perform routine IHC and antibody optimization and screening.
Dr. Chanthaphavong explained how the use of serial sections and chromogenic immunohistochemistry (IHC) is insufficient to study the tumor microenvironment.
“Using serial sections and chromogenic IHC has been difficult to study the dynamic and phenotypic changes of cell subsets during activation or differentiation, or to really understand how cell subsets respond to treatment,” said Dr. Chanthaphavong.
To overcome these challenges, Dr. Chanthaphavong and her team made the decision to adopt Akoya’s Vectra® 3 and Vectra® Polaris™ imaging systems for multiplexed, high-throughput spatial analysis of FFPE tumor samples. Investigators can analyze up to eight tissue biomarkers simultaneously on the Vectra® Polaris™ system, and up to six on the Vectra® 3. By adopting these platforms, the Experimental Histopathology Core Lab was able to increase their output and turnaround time to better support Fred Hutchinson researchers.